Gilead’s EVOKE-02 study of Trodelvy, KEYTRUDA combo shows promise in NSCLC

Gilead Sciences, Inc. announced early data showcasing promising clinical activity of Trodelvy in combination with Merck's KEYTRUDA for first-line treatment of metastatic non-small cell lung ... Read More